RTTNews | Jul 19, 2021 09:56AM EDT

09:56 Monday, July 19, 2021 (RTTNews.com) - Cytokinetics, Inc. (CYTK) shares are spiking on Monday morning trade after the company reported positive results from the phase 2 trial of CK-274, a cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy or HCM.

The company said the multi-center, placebo-controlled, double-blind randomized evaluation of dosing with CK-274 in obstructive outflow disease or REDWOOD in HCM for 10 weeks resulted in a statistically significant reduction in baseline compared to placebo.

Currently, shares are at $30.97, up 57.25 percent from the previous close of $19.23 on a volume of 12,919,059. For the 52-week period, the shares have traded in a range of $14.71-$31.00 on average volume of 766,165.

Read the original article on RTTNews ( https://www.rttnews.com/3209980/cytokinetics-gains-57-after-reporting-positive-results-of-ck-274-in-hypertrophic-cardiomyopathy.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved